Ultane is a brand name of sevoflurane, approved by the FDA in the following formulation(s):
ULTANE (sevoflurane - liquid; inhalation)
Manufacturer: ABBOTT
Approval date: June 7, 1995
Strength(s): 100% [RLD][AN]
Has a generic version of Ultane been approved?
A generic version of Ultane has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ultane and have been approved by the FDA:
sevoflurane liquid; inhalation
Manufacturer: BAXTER HLTHCARE
Approval date: July 2, 2002
Strength(s): 100% [AN]
Manufacturer: HALOCARBON PRODS
Approval date: November 19, 2007
Strength(s): 100% [AN]
SOJOURN (sevoflurane liquid; inhalation)
Manufacturer: PIRAMAL CRITICAL
Approval date: May 2, 2007
Strength(s): 100% [AN]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultane. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Patent 5,990,176
Issued: November 23, 1999
Inventor(s): Bieniarz; Christopher & Chang; Steve H. & Cromack; Keith R. & Huang; Shuyen L. & Kawai; Toshikazu & Kobayashi; Manami & Loffredo; David & Raghavan; Rajagopalan & Speicher; Earl R. & Stelmach; Honorate A.
Assignee(s): Abbott Laboratories
Central Glass Company Ltd.
The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.Patent expiration dates:
- January 27, 2017
- July 27, 2017✓
- January 27, 2017
Container for an inhalation anesthetic
Patent 6,074,668
Issued: June 13, 2000
Inventor(s): Flament-Garcia; Mary Jane & Chang; Steve H. & Cromack; Keith R. & Garapolo; Joan & Loffredo; David & Raghavan; Rajagopalan & Ramsay; George M. & Rice; Patrick & Setesak; Jeffrey
Assignee(s): Abbott Laboratories
A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing polyethylene napthalate. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.Patent expiration dates:
- January 9, 2018
- July 9, 2018✓
- January 9, 2018
Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Patent 6,288,127
Issued: September 11, 2001
Inventor(s): Bieniarz; Christopher & Chang; Steve H. & Cromack; Keith R. & Huang; Shuyen L. & Kawai; Toshikazu & Kobayashi; Manami & Loffredo; David & Raghavan; Rajagopalan & Speicher; Earl R. & Stelmach; Honorate A.
Assignee(s): Abbott Laboratories & Central Glass Co LTD
The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.Patent expiration dates:
- January 27, 2017
- July 27, 2017✓
- January 27, 2017
Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Patent 6,444,859
Issued: September 3, 2002
Inventor(s): Christopher; Bieniarz & Steve H.; Chang & Keith R.; Cromack & Shuyen L.; Huang & Toshikazu; Kawai & Manami; Kobayashi & David; Loffredo & Rajagopalan; Raghavan & Earl R.; Speicher & Honorate A.; Stelmach
Assignee(s): Abbott Laboratories
Central Glass Company LTD
The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.Patent expiration dates:
- January 27, 2017
- July 27, 2017✓
- January 27, 2017
See also...
- Ultane Consumer Information (Drugs.com)
- Ultane Consumer Information (Wolters Kluwer)
- Ultane Advanced Consumer Information (Micromedex)
- Sevoflurane Consumer Information (Wolters Kluwer)
- Ultane Amerinet Advanced Consumer Information (Micromedex)
- Ultane Novation Advanced Consumer Information (Micromedex)
- Sevoflurane Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
No comments:
Post a Comment